GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kronos Bio Inc (NAS:KRON) » Definitions » Market Cap

Kronos Bio (Kronos Bio) Market Cap : $60.04 Mil (As of Apr. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kronos Bio Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Kronos Bio's share price for the quarter that ended in Dec. 2023 was $1.25. Kronos Bio's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 58.95 Mil. Therefore, Kronos Bio's market cap for the quarter that ended in Dec. 2023 was $73.68 Mil.

Kronos Bio's quarterly market cap declined from Jun. 2023 ($99.97 Mil) to Sep. 2023 ($75.63 Mil) and declined from Sep. 2023 ($75.63 Mil) to Dec. 2023 ($73.68 Mil).

Kronos Bio's annual market cap declined from Dec. 2021 ($757.01 Mil) to Dec. 2022 ($92.29 Mil) and declined from Dec. 2022 ($92.29 Mil) to Dec. 2023 ($73.68 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Kronos Bio's Enterprise Value for Today is $-85.83 Mil.


Kronos Bio Market Cap Historical Data

The historical data trend for Kronos Bio's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kronos Bio Market Cap Chart

Kronos Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial - 1,615.19 757.01 92.29 73.68

Kronos Bio Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.29 83.74 99.97 75.63 73.68

Competitive Comparison of Kronos Bio's Market Cap

For the Biotechnology subindustry, Kronos Bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kronos Bio's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kronos Bio's Market Cap distribution charts can be found below:

* The bar in red indicates where Kronos Bio's Market Cap falls into.



Kronos Bio Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Kronos Bio's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$1.25*58.946
=$73.68

Kronos Bio's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$1.25*58.946
=$73.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kronos Bio  (NAS:KRON) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Kronos Bio Market Cap Related Terms

Thank you for viewing the detailed overview of Kronos Bio's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Kronos Bio (Kronos Bio) Business Description

Traded in Other Exchanges
N/A
Address
1300 So. El Camino Real, Suite 300, San Mateo, CA, USA, 94402
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
Executives
Jorge Dimartino officer: Chief Medical Officer & VP C/O KRONOS BIO, INC., 1300 S, SAN MATEO CA 94402
Christopher Dinsmore officer: Chief Scientific Officer C/O KRONOS BIO, INC., 1300 EL CAMINO REAL, STE. 300, SAN MATEO CA 94402
Barbara Kosacz officer: COO & General Counsel 3175 HANOVER STREET, PALO ALTO CA 94304
Norbert W Bischofberger director, 10 percent owner, officer: President & CEO 333 LAKESIDE DR, C/O GILEAD SCIENCES, INC., FOSTER CITY CA 94404
Sandra A. Gardiner officer: Interim CFO CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Yasir B. Al-wakeel officer: Chief Financial Officer MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Roger D Dansey director 21823 30TH DRIVE SE, BOTHELL WA 98021
Katherine V Stultz director C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Backer Marianne De director 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jakob Loven director C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Taiyin Yang director 2631 HANOVER STREET, PALO ALTO CA 94304
Otello Stampacchia director, 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
John C Martin director 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Elena Ridloff director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130

Kronos Bio (Kronos Bio) Headlines

From GuruFocus

Kronos Bio Announces Participation in Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 07-01-2022

Kronos Bio Announces Participation in Upcoming Investor Conferences

By Value_Insider Value_Insider 11-22-2022